Browse 18 scientific publications and peer-reviewed studies related to Cortexin.
Degtyareva VG, Drobyshev VA, Poteryaeva EL
To evaluate the effectiveness of complex rehabilitation measures using the drug Cortexin in children with neuropsychiatric pathology during a one-year follow-up.
Shchepankevich LA, et al.
To evaluate the effect of Cortexin treatment on cognitive function and quality of life for young patients after ischemic stroke.
Kuznetsova EB, Selivanova JV, Gerber AV
Assessing the effectiveness of using a complex that includes the use of the drug Cortexin and classes using the mobile application Aphasia.No (Afaziyam.Net) in working with speech disorders in patients with acute stroke.
Melnik EA
To evaluate the efficacy of Cortexin in the treatment of patients with post-Covid impairment.
Yazar U, Ayar A
The aim of this study was to investigate whether Cortexin®, a brain peptide-containing agent, has any mitigating effect on high glucose-induced neuropathy, using primary cultured rat sensory neurons.
Putilina MV, et al.
To study the prevalence of clinical manifestations of postcoid syndrome in patients at an outpatient neurological appointment, to evaluate the effectiveness of therapy regimens using Cortexin at doses of 10 mg and 20 mg IM for 10 days.
Kurkin DV, et al.
To compare the antioxidant effects of cortexin, cerebrolysin and actovegin in rats with chronic brain ischemia.
V Kalmykova G, et al.
To study the possibility of using the polypeptide drug cortexin for the treatment of cognitive, emotional and behavioral disorders in children and adolescents with epilepsy and to assess the efficacy and safety of the drug in this group of patients.
Lysenko AV, et al.
The two-week use of special breathing exercises in combination with the Cortexin peptide bioregulator optimizes the functional state and increases the professional performance of older teachers more effectively compared to the single use of a pharmacological preparation. The maximum effect is noted immediately after the end of the course use of special breathing exercises and the peptide bioregulator and lasts for two months. The results obtained open up prospects for the use of breathing exercises to enhance and prolong the nootropic drugs and antihypoxants antistress and geroprotective effects.
Khabirov FA, et al.
To compare the efficacy of Cellex and Cortexin in patients in the early recovery period of ischemic stroke (ERPIS) receiving basic therapy (BT).
Belova LA, et al.
To make a critical assessment of the therapeutic effect of complex therapy with cortexin and recognan (citicoline) for cognitive impairments in patients with chronic cerebrovascular pathology.
Zykov VP, et al.
To study the efficacy and tolerability of cortexin in the treatment of cognitive dysfunction in children.
Eroğlu O, et al.
The aim of this report is to evaluate whether cortexin provides any protective activity against ototoxicity of cisplatin.
Gulyaeva NV
The goal of treatment of brain pathologies may be regarded as re-establishment of optimal brain plasticity. Disturbances in neuroplasticity are associated with the appearance of multiple targets that should be subjects for pharmacological correction. Peptide hydrolysates derived from animal brain became a basis for multi-component organ-specific drugs which are widely used for treatment of cerebral pathologies. Potentially, the presence of many components in such drugs may be beneficial for simultaneous effects on different targets. In this article, new data are analyzed related to relevant molecular mechanisms underlying neuroprotective properties of cortexin. On a model of accelerated aging in rats, cortexin restored the ratio of pro- and antioxidative systems and demonstrated a significant anti-inflammatory effect both in the brain and at the systemic level. In in vitro experiments cortexin effectively and tissue-specifically inhibited brain caspase-8. Neuron-specific proteins β5-tubulin, creatine kinase B and protein 14-3-3 α/β were shown to be molecular partners of cortexin peptides in the brain. Thus, potential molecular mechanisms of cortexin neuroprotective effects are various and associated with key processes underlying neuroplasticity: signal transduction, energy metabolism, proteolytic protein modification, cell structure, as well as neuroinflammation. The pleiotropicity of mechanisms of cortexin action is based on the composition of the drug containing a variety of neuropeptides. The tissue specificity of these mechanisms determines to a significant degree the efficacy of the drug in treatment of cerebral pathologies.
Yakovlev AA, et al.
Cortexin, a drug containing hydrolyzed brain peptides, has long been used in clinics, but the mechanisms of its action remain obscure. We have hypothesized that cortexin-related neuroprotection is associated with the ability of the drug to inhibit brain proteases. Cortexin effectively inhibited brain caspase-8, while its effects on caspase-1, -3, -9, cathepsin B and calpain were much less pronounced or absent. In addition, we isolated a peptide fraction from cortexin holding all the inhibitory capacity of the original drug, but with a much more simple composition. Both cortexin and its fraction prevented neuronal damage in a culture model of glutamate-induced cell death. Neuroprotective effect of Cortexin may be mediated by inhibition of the initiator caspase-8 in the brain.
Tunçcan T, et al.
The aim was to investigate the efficacy of cortexin and methylprednisolone on recovery in cases of traumatic facial nerve paralysis occurring after facial nerve trauma.
Reutov VP, et al.
Shabanov PD, et al.
We compared central effects of polypeptide preparations cortexin and cerebrolysin injected into brain ventricles of Wistar rats in doses of 1, 10, and 100 microg. Both drugs exhibited moderate psychoactivating effect, the effects cortexin were more pronounced compared to those of cerebrolysin in all tests.